NCT02360774

Mechanisms of Weight Loss With SGLT2 Inhibition

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Beth Israel Deaconess Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the effect of canagliflozin, a medication approved by the FDA for the treatment of type 2 diabetes, on body weight and metabolism in people with type 2 diabetes who are overweight or obese. Canagliflozin lowers glucose levels in the blood by making the kidneys excrete, rather than absorb, glucose. Canagliflozin is also often associated with weight loss. The study population will generally be type 2 diabetics, ages 18-75 years old, who are overweight or obese.

Conditions

• Type 2 Diabetes
• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	Canagliflozin	Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
DRUG	Placebo	Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.

Timeline

• Start date: 2015-02-01
• Primary completion: 2018-08-01
• Completion: 2018-08-01
• First posted: 2015-02-11
• Last updated: 2018-08-03
• Results posted: 2018-08-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study